Abstract:Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes that negatively regulate the immune response to cancer and chronic infections. Abnormal myelopoiesis and pathological activation of myeloid cells generate this heterogeneous population of myeloid-derived suppressor cells. They are characterized by their distinct transcription, phenotypic, biochemical, and functional features. In the tumor microenvironment (TME), myeloid-derived suppressor cells represent an important class of immunosuppressive cells that correlate with tumor burden, stage, and a poor prognosis. Myeloid-derived suppressor cells exert a strong immunosuppressive effect on T-cells (and a broad range of other immune cells), by blocking lymphocyte homing, increasing production of reactive oxygen and nitrogen species, promoting secretion of various cytokines, chemokines, and immune regulatory molecules, stimulation of other immunosuppressive cells, depletion of various metabolites, and upregulation of immune checkpoint molecules. Additionally, the heterogeneity of myeloid-derived suppressor cells in cancer makes their identification challenging. Overall, they serve as a major obstacle for many cancer immunotherapies and targeting them could be a favorable strategy to improve the effectiveness of immunotherapeutic interventions. However, in hematological malignancies, particularly B-cell malignancies, the clinical outcomes of targeting these myeloid-derived suppressor cells is a field that is still to be explored. This review summarizes the complex biology of myeloid-derived suppressor cells with an emphasis on the immunosuppressive pathways used by myeloid-derived suppressor cells to modulate T-cell function in hematological malignancies. In addition, we describe the challenges, therapeutic strategies, and clinical relevance of targeting myeloid-derived suppressor cells in these diseases.

Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways

Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies

Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer

Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer

Myeloid-derived Suppressor Cells and Multiple Sclerosis

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation

Interleukin 33 in Tumor Microenvironment is Crucial for the Accumulation and Function of Myeloid-Derived Suppressor Cells

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Myeloid-derived suppressor cells as regulators of the immune system

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy

Myeloid-Derived Suppressor Cells Endow Stem-Like Qualities To Breast Cancer Cells Through Il6/Stat3 And No/Notch Cross-Talk Signaling

Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy

Myeloid-Derived Suppressor Cells: Ductile Targets in Disease

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies

Recent Progress on MDSCs and Tumor Immune Tolerance

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy

Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway